These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24369083)

  • 1. Tumor necrosis factor inhibitors for inflammatory bowel disease.
    Peyrin-Biroulet L
    N Engl J Med; 2013 Dec; 369(26):2561. PubMed ID: 24369083
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor necrosis factor inhibitors for inflammatory bowel disease.
    Coskun M; Nielsen OH
    N Engl J Med; 2013 Dec; 369(26):2561-2. PubMed ID: 24369082
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumor necrosis factor inhibitors for inflammatory bowel disease.
    Nielsen OH; Ainsworth MA
    N Engl J Med; 2013 Aug; 369(8):754-62. PubMed ID: 23964937
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor therapies. Foreword.
    Magro F
    BioDrugs; 2010 Dec; 24 Suppl 1():1-2. PubMed ID: 21175227
    [No Abstract]   [Full Text] [Related]  

  • 5. Antitumor necrosis factor, infliximab, and adalimumab: use with caution in eosinophilic bowel disease.
    Furuta GT; Atkins D; Capocelli KE; de Zoeten EF; Fleischer D; Menard-Katcher C
    J Pediatr Gastroenterol Nutr; 2013 Oct; 57(4):e25. PubMed ID: 23820407
    [No Abstract]   [Full Text] [Related]  

  • 6. Reader response: antitumor necrosis factor therapy.
    Heath PK; Athwal D; Jones S
    Inflamm Bowel Dis; 2000 Feb; 6(1):70. PubMed ID: 10701157
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of biologics in inflammatory bowel disease patients with cirrhosis.
    Dhere T
    Inflamm Bowel Dis; 2011 Feb; 17(2):E15-6. PubMed ID: 20878757
    [No Abstract]   [Full Text] [Related]  

  • 8. Authors' response.
    Turner D; Friesen C
    J Pediatr Gastroenterol Nutr; 2013 Oct; 57(4):e25-6. PubMed ID: 23820406
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic.
    Licinio R; Losurdo G; Ierardi E; Di Leo A; Principi M
    Aliment Pharmacol Ther; 2015 Jun; 41(12):1302. PubMed ID: 25968153
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFalpha reduce colitis-associated colorectal carcinogenesis?
    Biancone L; Petruzziello C; Calabrese E; Zorzi F; Naccarato P; Onali S; Pallone F
    Gut; 2009 Dec; 58(12):1703. PubMed ID: 19923350
    [No Abstract]   [Full Text] [Related]  

  • 11. Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure.
    Macaluso FS; Criscuoli V; Orlando E; Rizzuto G; Renna S; Cottone M; Orlando A
    Aliment Pharmacol Ther; 2016 May; 43(9):1019-20. PubMed ID: 27040168
    [No Abstract]   [Full Text] [Related]  

  • 12. Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic. Authors' reply.
    Gisbert JP; Chaparro M
    Aliment Pharmacol Ther; 2015 Jun; 41(12):1302-3. PubMed ID: 25968154
    [No Abstract]   [Full Text] [Related]  

  • 13. [Application of TNF-alpha blocker concentration assays in the treatment of inflammatory bowel diseases].
    Sipponen T; Kolho KL
    Duodecim; 2013; 129(5):499-505. PubMed ID: 23520893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure--authors' reply.
    Gisbert JP; Chaparro M
    Aliment Pharmacol Ther; 2016 May; 43(9):1020. PubMed ID: 27040169
    [No Abstract]   [Full Text] [Related]  

  • 15. TREM1 predicts response to anti-tumor necrosis factor in inflammatory bowel diseases: Towards precision medicine.
    Felice C; Pugliese D; Guidi L
    EBioMedicine; 2019 Mar; 41():40-41. PubMed ID: 30808577
    [No Abstract]   [Full Text] [Related]  

  • 16. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases.
    Olesen CM; Coskun M; Peyrin-Biroulet L; Nielsen OH
    Pharmacol Ther; 2016 Mar; 159():110-9. PubMed ID: 26808166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.
    Peng JC; Shen J; Ran ZH
    J Dig Dis; 2014 Nov; 15(11):585-90. PubMed ID: 25251263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us?
    Akobeng AA; Sandborn WJ; Bickston SJ; Chande N; Shackelton LM; Nelson S; Feagan BG
    Inflamm Bowel Dis; 2014 Nov; 20(11):2132-41. PubMed ID: 25299543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Perspectives in inflammatory bowel diseases treatment].
    Jalocha L; Wojtuń S; Dyrla P; Błaszak A; Wojtkowiak M; Zyśko B; Stelmaszuk T; Gil J
    Pol Merkur Lekarski; 2009 May; 26(155):556-8. PubMed ID: 19606725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Practical use of anti-TNF monoclonal antibodies in inflammatory bowel diseases].
    Allez M
    Gastroenterol Clin Biol; 2008 May; 32(5 Pt 1):467-77. PubMed ID: 18448294
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.